ARS Pharmaceuticals Inc.'s (SPRY) flagship product, neffy, has been enjoying strong commercial growth since launch, helped by growing patient awareness and increasing clinician confidence in its efficacy.
Neffy (epinephrine nasal spray) is the first and only FDA- and European Commission-approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis, and represents the first new delivery method for epinephrine in over 35 years. It gained approval in the U.S. and EU in August 2024, with the U.K., Japan, and China following with regulatory approvals in 2025. Approval is expected this quarter in Canada, expanding its global availability.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.